Literature DB >> 7653020

Geographical and temporal patterns of incidence and mortality from prostate cancer.

P Boyle1, P Maisonneuve, P Napalkov.   

Abstract

In many countries of the world, prostate cancer is the second most common form of cancer in men, and in the United States it is now in first rank. It is an important public health problem, with > 0.25 million new cases diagnosed worldwide in the year 1985. Whereas earlier large increases in the incidence of prostate cancer were apparent throughout the world, the mortality rate has remained constant in generations of men born since the early years of this century. Most importantly, given that in several countries the increased number of children born after World War II will be in their mid-50s in the early part of the 21st century (at an age when cancer risk is becoming an important consideration), and coupled with the trends in increasing life expectancy, the consequence will be an increase in absolute terms in the number of cases of prostate cancer diagnosed. In the absence of treatment improvements and with prospects for prevention by modification of lifestyle remote within current knowledge, there will also be an increase in the number of deaths from prostate cancer worldwide. The situation would be further augmented by the presence of a temporal trend in risk that is widely reported from many countries and unlikely to be entirely artefact.

Entities:  

Mesh:

Year:  1995        PMID: 7653020     DOI: 10.1016/s0090-4295(99)80250-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

1.  AXIN2 polymorphism and its association with prostate cancer in a Turkish population.

Authors:  Ergun Pinarbasi; Emine Gulsen Gunes; Hatice Pinarbasi; Gonca Donmez; Yavuz Silig
Journal:  Med Oncol       Date:  2010-11-11       Impact factor: 3.064

2.  Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older.

Authors:  Mohammad Reza Safarinejad
Journal:  Int Urol Nephrol       Date:  2008-02-02       Impact factor: 2.370

3.  Does screening for prostate cancer identify clinically important disease?

Authors:  M R Feneley
Journal:  Ann R Coll Surg Engl       Date:  1999-05       Impact factor: 1.891

4.  Testicular metastases: a poor prognostic factor in patients with advanced prostate cancer.

Authors:  Fernando Korkes; Renato Gasperini; Karen Levy Korkes; Deusdedit Cortez Vieira Silva Neto; Marilia Germanos Castro
Journal:  World J Urol       Date:  2008-09-02       Impact factor: 4.226

5.  Inhibitory effect of resveratrol against duck enteritis virus in vitro.

Authors:  Jiao Xu; Zhongqiong Yin; Li Li; Anchun Cheng; Renyong Jia; Xu Song; Hongke Lu; Shujun Dai; Cheng Lv; Xiaoxia Liang; Changliang He; Ling Zhao; Gang Su; Gang Ye; Fei Shi
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

6.  Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells.

Authors:  Sharmila Shankar; Imtiaz Siddiqui; Rakesh K Srivastava
Journal:  Mol Cell Biochem       Date:  2007-07-17       Impact factor: 3.396

7.  Animal products, calcium and protein and prostate cancer risk in The Netherlands Cohort Study.

Authors:  A G Schuurman; P A van den Brandt; E Dorant; R A Goldbohm
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

Review 8.  Lactate transporters in the context of prostate cancer metabolism: what do we know?

Authors:  Nelma Pértega-Gomes; Fátima Baltazar
Journal:  Int J Mol Sci       Date:  2014-10-13       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.